List view / Grid view
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
The mechanism that prevents destruction of cancer cells by CAR T-cell therapy has been identified by researchers in Pennsylvania.
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in paediatric and adult patients with advanced HER2-positive sarcoma...
When a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumour growth for up to 20 days in mice...
The 13th annual World Advanced Therapies & Regenerative Medicine Congress brings together 1000+ attendees and explores the rapidly developing world of next generation therapeutics and ATMPS.
21 June 2016 | By Victoria White, Digital Content Producer
A Penn Medicine preclinical study shows how an antibody - carbohydrate combination CAR T cell therapy could apply to range of cancer types...
